SLC16A1 and neoplasm: Consistently, elevated expression of MCT1 was observed in efficiently metastasising melanoma cells, and treatment with a selective MCT1 inhibitor (AZD3965) depleted circulating melanoma cells and reduced metastatic disease burden with little effect on primary tumour growth [29].